Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Novartis ($NVS), at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer's disease, adding measures of brain function to an ongoing trial. As The Wall Street Journal points out, Novartis is responding to a paper published this month warning that the drug, LCZ696, could inadvertently interrupt the body's natural method of fighting the plaques thought to cause Alzheimer's. No study on the drug has charted any evidence of cognitive decline, Novartis said, but the company is expanding its evaluation of the issue quot;to provide an answer to the scientific community," an executive told the Journal. More (sub. req.)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.